Mestag Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

Contributed by: GlobeNewswire

Tags

cancer

More Like This

Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel

Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300

Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases

Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program

Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

Business Wire logo

ReNAgade Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference

PR Newswire associated0

FibroBiologics to Provide Company Update at Upcoming Conferences

Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting